Spark Therapeutics says ‘responsible price’ for Luxturna gene therapy ensures access for patients with retinal defectA drug whose inventors claim it can cure a scarce form of blindness is to be one of the most expensive medicines ever sold at $850000 (£630000).
Luxturna is injected directly into the eye to address the root cause of visual impairment by replacing a faulty gene in the retina. It is the first gene therapy to be approved for exercise in the US,and was given the go-ahead by the Federal Drug Administration last month. However, the price of the treatment has only just been revealed.
Continue reading...
Source: guardian.co.uk